JP2003528609A5 - - Google Patents

Info

Publication number

JP2003528609A5

JP2003528609A5 JP2001570742A JP2001570742A JP2003528609A5 JP 2003528609 A5 JP2003528609 A5 JP 2003528609A5 JP 2001570742 A JP2001570742 A JP 2001570742A JP 2001570742 A JP2001570742 A JP 2001570742A JP 2003528609 A5 JP2003528609 A5 JP 2003528609A5

Authority

JP

Japan

Prior art keywords

fragment

protein

angiogenic activity

isolated

domain

Prior art date

2001-03-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 description 23
• 230000001772 anti-angiogenic effect Effects 0.000 description 17
• 102000004169 proteins and genes Human genes 0.000 description 17
• 108090000623 proteins and genes Proteins 0.000 description 17
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
• 210000004899 c-terminal region Anatomy 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 108010008217 nidogen Proteins 0.000 description 5
• 239000003814 drug Substances 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 2
• 102100037369 Nidogen-1 Human genes 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 238000000034 method Methods 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• 241000144080 Alestes Species 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 102400000729 Arresten Human genes 0.000 description 1
• 101800001248 Arresten Proteins 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 102400000730 Canstatin Human genes 0.000 description 1
• 101800000626 Canstatin Proteins 0.000 description 1
• 208000003732 Cat-scratch disease Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 102400001051 Restin Human genes 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 102400000731 Tumstatin Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000013058 Weber syndrome Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 201000007293 brain stem infarction Diseases 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 230000002254 contraceptive effect Effects 0.000 description 1
• 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 229960003738 meticrane Drugs 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 150000007523 nucleic acids Chemical group 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1